Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Work In Process (2016 - 2019)

Tandem Diabetes Care filings provide 6 years of Work In Process readings, the most recent being $3.6 million for Q1 2019.

  • On a quarterly basis, Work In Process fell 5.34% to $3.6 million in Q1 2019 year-over-year; TTM through Mar 2019 was $3.6 million, a 5.34% decrease, with the full-year FY2018 number at $2.7 million, down 28.91% from a year prior.
  • Work In Process hit $3.6 million in Q1 2019 for Tandem Diabetes Care, up from $2.7 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $6.6 million in Q2 2017 to a low of $2.6 million in Q2 2015.
  • Median Work In Process over the past 5 years was $3.8 million (2017), compared with a mean of $4.2 million.
  • Biggest five-year swings in Work In Process: surged 74.78% in 2016 and later crashed 52.51% in 2018.
  • Tandem Diabetes Care's Work In Process stood at $3.4 million in 2015, then grew by 29.49% to $4.4 million in 2016, then dropped by 13.27% to $3.8 million in 2017, then decreased by 28.91% to $2.7 million in 2018, then skyrocketed by 31.37% to $3.6 million in 2019.
  • The last three reported values for Work In Process were $3.6 million (Q1 2019), $2.7 million (Q4 2018), and $4.5 million (Q3 2018) per Business Quant data.